ustekinumab as a treatment for crohn’s disease: efficacy and safety
Published 6 years ago • 5.4K plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
21:36
crohn's disease: recent and emerging therapies
-
12:58
positioning of biologics and new therapeutics for crohn's disease
-
22:11
crohn's disease: update on recent and emerging therapies
-
23:55
new biologic therapies that target the il-12/23 pathway
-
25:33
understanding the mechanisms of action of new agents: implications for efficacy and safety
-
20:09
recent and emerging crohn's disease therapies
-
20:08
biologics and mucosal healing in crohn’s disease: available evidence
-
15:15
first line therapies for ulcerative colitis and crohn's disease
-
4:57
crohn’s disease: clinical experience with ustekinumab
-
4:49
ustekinumab as the new frontline treatment
-
4:56
ustekinumab (stelara) - ibd treatments explained by the experts
-
22:05
understanding the use of il12/il23 targeted biologics
-
23:44
mechanisms of disease: biologic pipeline for ibd
-
26:10
recent and emerging ulcerative colitis therapies
-
3:19
treatment persistence of ustekinumab in crohn’s disease - video abstract [id 310076]
-
18:38
positioning anti-il-12 and anti-il-23 inhibitors
-
49:17
the evolving therapeutic paradigm in ibd: optimal positioning of new and emerging agents
-
3:32
maria abreu, md: ustekinumab as a first line treatment for ulcerative colitis
-
12:15
ibd: safety and positioning of il-23 inhibitors under investigation